Investors in Cullinan Therapeutics Inc (Symbol: CGEM) saw new options become available today, for the April 2025 expiration. One of the key data points that goes into the price an option buyer is ...
Cullinan Therapeutics, Inc. has a cash-rich balance sheet and no financial debt while trading at a reasonable valuation. Read ...
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Applicatio ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cullinan Therapeutics Inc (Symbol: CGEM), where a total of 5,055 contracts have traded so ...
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The ...
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...
Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced ...
Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results